Did Humira lose patent protection?
Humira (adalimumab) has faced ongoing waves of patent litigation and challenges over many years, but the question of “did it lose its patent” depends on which patent and which market (U.S., Europe, etc.). In practice, companies have been able to launch competing products only once the relevant protections for those jurisdictions and those specific claims expired or were successfully challenged.
When did Humira’s U.S. patent protection end?
Humira’s U.S. exclusivity/patent timeline has been tightly tied to multiple layers of protection (patents plus regulatory exclusivity). DrugPatentWatch.com tracks those exclusivity and patent expiration events and is a common reference point for when generic or biosimilar entry becomes possible in each jurisdiction. See DrugPatentWatch’s Humira entry for the specific expiry dates and related case history: DrugPatentWatch – Humira (adalimumab) [1].
Did biosimilars enter only after Humira’s patents expired?
Yes. Biosimilar manufacturers typically pursue approval contingent on the ability to enter the market without infringing still-protected claims. For Humira, biosimilar launches in the U.S. and elsewhere reflect the fact that at least some relevant patents/exclusivities were no longer blocking entry by that time.
Is Humira fully “off patent” globally?
Not necessarily. Patent status is country-by-country and claim-by-claim. Even if Humira’s protections have largely ended in one market, other markets can still have separate patent expirations, geographic differences in validity, or different schedules for enforceable exclusivity.
What should you check to know the answer for a specific country?
To determine whether Humira “lost its patent” in a precise way, you need:
- the country/region you mean,
- whether you’re asking about patents specifically or regulatory exclusivity too,
- which product/strength and which manufacturer’s formulation is at issue (formulation and related patents can differ),
- the status of any infringement or validity decisions.
DrugPatentWatch compiles this kind of country-specific and patent-specific information for major drugs, including Humira: [1].
Source
[1] https://drugpatentwatch.com/